StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
LTRNLantern Pharma Inc.
stockpulse.co.kr
Nasdaq
$0.6167▼ 2.94%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $7.9MShares out 12.8M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

12
  • 4d agoPre-market26.10.21 07:46filed
    ARSOther#●●●#●●●

    Lantern Pharma Inc.

    Lantern Pharma Inc. has filed its Annual Report to Security Holders (ARS) for the fiscal year ended December 31, 2025. This filing provides shareholders with an overview of the company's annual financial position and business operations.…more

    $0.6167-2.94%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 5d agoAfter-hours26.10.20 05:15
    DEF 14AOther

    Lantern Pharma Inc.

    Lantern Pharma will hold its 2026 Annual Meeting on December 1, 2026, to vote on proposals including increasing authorized common stock to 50 million shares and approving the issuance of up to 3,669,725 shares upon the exercise of purchase warrants. The meeting also seeks approval to increase the shares available under the 2018 Equity Incentive Plan by 250,000, which may lead to future shareholder dilution.…more

    $0.6167-2.94%vs prev close
    View filingShare
  • 10.13Regular26.10.14 01:51
    SCHEDULE 13G/AOwnership

    Lantern Pharma Inc.

    Empery Asset Management, LP has filed an amended SCHEDULE 13G/A regarding its beneficial ownership in Lantern Pharma Inc. This filing serves as an official update to the SEC concerning the investor's equity position in the company.…more

    $0.6167-2.94%vs prev close
    View filingShare

11 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.7Pre-market26.10.07 21:38
    #●●●#●●●

    Lantern Pharma Receives Taiwan Approval for Phase 2 LP-300 Trial

    Lantern Pharma has received regulatory approval in Taiwan to advance its LP-300 Phase 2 clinical trial for never-smoker lung cancer. While this marks a progress in clinical development, the company remains in the early stages of commercialization.…more

    $0.6167-2.94%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.22Pre-market26.09.22 20:46

    ●●●●●●●● ●●●●● ●●●●●●

    Lantern Pharma has received a Notice of Allowance from the USPTO for its drug candidate LP-284. The patent covers methods for treating specific blood cancers, including mantle cell lymphoma and double-hit lymphoma.…more

    $0.6167-2.94%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →